Overview

A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection

Status:
Completed

Trial end date:
2015-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and efficacy of co-administration of ABT-450 (also known as paritaprevir) with ritonavir (ABT-450/r) and ABT-267 (also known as ombitasvir) in adults with chronic hepatitis C virus infection.

Phase:

Phase 2

Details

Lead Sponsor:

AbbVie (prior sponsor, Abbott)

Treatments:

Interferons
Ribavirin
Ritonavir